Monopar Therapeutics Inc. (MNPR)
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
📈 **POSITIVE** • Medium confidence analysis (72%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (84%) **Content type:** Clinical